Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Formulation
Sort By
Newest First
1 / 10
1 / 10
Particle ID
Leveraging Formulation Development Experience for Effective Particle Identification
Jörg Müller, Ph.D.
Coriolis Pharma
PAO-10-24-CL-10
Nov 18, 2024
Minitablets
Minitablets: Enhancing Safety and Palatability for Pediatric Medicines
Gus LaBella
Mikart
PAO-09-24-CL-01
Aug 30, 2024
Drug Delivery
Nanocarriers to Overcome the Blood–Brain Barrier (BBB)
Serene Lee
Nice Insight
PAO-09-24-NI-01
Aug 30, 2024
Developability
Assessing Developability and Designing Advanceable Formulations from the Start
Nazar Elkarim, Ph.D.
Mikart
PAO-09-24-CL-02
Aug 26, 2024
Developability
Streamlining the Path to Approval with Developability and Pre-Formulation Platforms
Andrea Hawe
Coriolis Pharma
PAO-07-24-CL-11
Aug 01, 2024
CRDO
Partnering with Scientific Excellence to De-Risk and Accelerate Drug Development
Silvia Steyrer-Gruber
Coriolis Pharma
PAO-07-24-CL-05
Jul 16, 2024
Liquid Suspensions
Beyond Pills: the Rise of Liquid Suspensions for Complex Formulations
Gus LaBella
Mikart
PAO-07-24-CL-04
Jul 09, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02
Jun 18, 2024
Lipid Nanoparticles
Feasibility Studies and cGMP Design Supporting Continuous Lipid Nanoparticle Manufacturing
Jim Ziogas
DIANT Pharma
PAO-05-24-CL-03
May 30, 2024
mRNA Innovations
Technology Advances Needed to Drive Future mRNA Growth
Hagen Richter, Ph.D.
PAO-04-24-CL-04
Apr 15, 2024
mRNA–LNP Manufacturing
The Innovators Bringing Continuous Manufacturing to Lipid Nanoparticles
Antonio Costa, Ph.D.; William Pasek
DIANT Pharma
PAO-03-24-CL-08
Mar 18, 2024
Advanceability
Right from the Start: Designing Advanceable Formulations and Processes at Phase I
Serán Bioscience
PAO-02-24-CL-09
Feb 26, 2024
Biologics Formulation
Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform
Pawel Stanczak, Ph.D.
Tanvex CDMO
PAO-02-24-CL-02
Feb 15, 2024
CDMO
Maximizing Outsourcing Benefits for Virtual Pharma Companies
William Kazimier
Tedor Pharma Services
PAO-09-23-CL-08
Jan 11, 2024
Lipid Nanoparticles
Facilitating Development and Scale-Up of Nanoparticle Drug Products with an End-to-End Adaptable Manufacturing Platform
Antonio Costa, Ph.D.
DIANT Pharma
PAO-10-23-CL-03
Nov 01, 2023
Failing Fast
Maximizing Resources and Potential for Success by Failing Fast
Nazar Elkarim, Ph.D.
Mikart
PAO-10-23-CL-02
Oct 23, 2023
Formulation
Addressing Swallowing and Palatability Issues with Patient-Friendly Dosage Forms
Gus LaBella
Mikart
PAO-09-23-CL-04
Oct 03, 2023
CDMO
Redesigning ANDA or Novel Drug Products at All Stages for the U.S. Market
Tedor Pharma Services
PAO-08-23-CL-06
Sep 26, 2023
Viscosity Reduction
Viscosity Reduction with An Excipient Platform and Feasibility Testing Service
Alana Gouveia
MilliporeSigma
PAO-08-23-CL-03
Aug 10, 2023
Alternative Excipient
Preparing Today for a Potential Ban on Titanium Dioxide in Pharmaceutical Drug Products
Almut von der Brelie
MilliporeSigma
PAO-08-23-CL-01
Aug 03, 2023
